Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negative breast cancer (Abstract LBA14).
Cora N. Sternberg, MD, of the San Camillo Forlanini Hospital, summarizes a session on the STAMPEDE and LATITUDE trials, as well as a third trial on docetaxel with androgen suppression for localized prostate cancer patients who relapsed after radical prostatectomy and/or radiotherapy (Abstracts LBA31, 783O, 784O).
Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combination therapy with PI3K were discussed.
Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metastatic renal cell carcinoma (Abstract 1137O).
Bernard J. Escudier, MD, of Gustave Roussy, offers a roundup of the important papers on renal cell cancer presented at this year's ESMO Congress.
Robert I. Haddad, MD, of Dana-Farber Cancer Institute, discusses phase III study results on treatment beyond disease progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (Abstract 1043O).
